Eytan Stein, MD

Eytan M. Stein, MD, discusses efficacy findings from the phase 1/2 AUGMENT-101 study of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.

Eytan M. Stein, MD, discusses how the FDA approval of revumenib could improve survival outcomes in KMT2A-rearranged relapsed/refractory acute leukemia.

Eytan M. Stein, MD, discusses the ongoing development and investigation of therapies targeting splicing mutations in hematologic malignancies.

Eytan M. Stein, MD, discusses the phase 2 SELECT-AML-1 trial in patients with newly diagnosed acute myeloid leukemia.

Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, discusses new data from a phase I study exploring the oral IDH2 inhibitor AG-221 in patients with advanced hematologic malignancies, primarily acute myelogenous leukemia and myelodysplastic syndrome.